An Exploratory Study of the Effects of 12 Month Administration of the Novel Long-Acting Testosterone Undecanoate on Measures of Sexual Function and the Metabolic Syndrome

REFERENCES

• Bansal, T. C., Guay, A. T., Jacobson, J., Woods B. O. and Nesto, R. W. (2005). Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med 2:96–103.
   PubMed Web of Science ®Google Scholar
• Dobs, A. S., Meikle, A. W., Arver, S., Sanders, S. W., Caramelli, K. E. and Mazer, N. A. (1999). Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 84:3469–3478.
   PubMed Web of Science ®Google Scholar
• Ford, E. S. (2005). Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28:2745–2749.
   PubMed Web of Science ®Google Scholar
• Grover, S. A., Lowensteyn, I., Kaouache, M., Marchand, S., Coupal, L., DeCarolis, E., Zoccoli, J. and Defoy, I. (2006). The prevalence of erectile dysfunction in the primary care setting importance of risk factors for diabetes and vascular disease. Arch Intern Med 166:213–219.
   PubMed Web of Science ®Google Scholar
• Grundy, S. M., Brewer, H. B. Jr., Cleeman, J. I., Smith, S. Jr. and Lenfant, C. (2004) Definition of metabolic syndrome report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24:e13–18.
   PubMed Web of Science ®Google Scholar
• Harle, L., Basaria, S. and Dobs, A. S. (2005). Nebido A long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 6:1751–1759.
   PubMed Web of Science ®Google Scholar
• Jackson, G. (2006). The Metabolic Syndrome and Erectile Dysfunction Multiple Vascular Risk Factors and Hypogonadism. Eur Urol. 50:426–427.
   PubMed Web of Science ®Google Scholar
• Jockenhovel, F., Vog, E., Reinhardt, W. and Reinwein, D. (1997). Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 2:293–298.
   PubMedGoogle Scholar
• Kalme, T., Seppala, M., Qiao, Q., Koistinen, R., Nissinen, A., Harrela, M., Loukovaara, M., Leinonen, P. and Tuomilehto, J. (2005). Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 90:1550–1556.
   PubMed Web of Science ®Google Scholar
• Kupelian, V., Shabsigh, R., Araujo, A. B., O'Donnell, A. B. and McKinlay, J. B. (2006a). Erectile dysfunction as a predictor of the metabolic syndrome in aging men Results from the Massachusetts Male Aging Study. J Urol 176:258–266.
   Google Scholar
• Kupelian, V., Page, S. T., Araujo, A. B., Travison, T. G., Bremner, W. J. and McKinlay, J. B. (2006b). Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91:843–850.
   PubMed Web of Science ®Google Scholar
• Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T. P., Salonen, R., Rauramaa, R. and Salonen, J. T. (2003). Sex hormones, inflammation and the metabolic syndrome A population-based study. Eur J Endocrinol 149:601–608.
   PubMed Web of Science ®Google Scholar
• Laaksonen, D. E., Niskanen, L., Punnonen K., Nyyssonen, K., Tuomainen T. P., Valkonen V. P., Salonen R. and Salonen, J. T. (2004). Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036–1041.
   PubMed Web of Science ®Google Scholar
• Nieschlag, E. (2006). Testosterone treatment comes of age New options for hypogonadal men. Clin Endocrinol (Oxf) 65:275–281.
   PubMed Web of Science ®Google Scholar
• Nieschlag, E., Swerdloff, R., Behre, H. M., Gooren, L. J., Kaufman, J. M., Legros, J. J., Lunenfeld, B., Morley, J. E., Schulman, C., Wang, C., (2005) Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 48:1–4.
   PubMed Web of Science ®Google Scholar
• Niskanen, L., Laaksonen, D. E., Punnonen, K., Mustajoki, P., Kaukua, J. and Rissanen, A. (2004) Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 6:208–215.
   PubMed Web of Science ®Google Scholar
• Page, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J. and Tenover, J. L. (2005). Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502–1510.
   PubMed Web of Science ®Google Scholar
• Schubert, M., Minnemann, T., Hubler, D., Rouskova, D., Christoph, A., Oettel, M., Ernst, M, Mellinger, U., Krone, W. and Jockenhovel, F. (2004). Intramuscular testosterone undecanoate Pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89:5429–5434.
   PubMed Web of Science ®Google Scholar
• Strain, G., Zumoff, B., Rosner, W. and Pi-Sunyer, X. (1994). The relationship between serum levels of insulin and sex hormone-binding globulin in men the effect of weight loss. J Clin Endocrinol Metab 79:1173–1176.
   PubMed Web of Science ®Google Scholar
• Vermeulen, A., Kaufman, J. M. and Giagulli, V. A. (1996). Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 81:1821–1826.
   PubMed Web of Science ®Google Scholar
• Vermeulen, A., Verdonck, L. and Kaufman, J. M. (1999). A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672.
   PubMed Web of Science ®Google Scholar
• von Eckardstein, S. and Nieschlag, E. (2002). Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks A phase II study. J Androl 23:419–425.
   PubMedGoogle Scholar